Announcement • Jun 30
Futura Medical Reports Highly Positive Data From WSD4000 Studies Futura Medical reported the results from two studies on WSD4000: the Home User Test ('HUT') and the Placebo (Sham) Controlled Study. The positive results from both studies enhance the Company's belief in the commercial potential for WSD4000 and demonstrate that WSD4000 is superior to placebo (sham) thereby enabling it to proceed with the clinical study with high confidence of success. The Company expects to commence the clinical study by the end of 2026, subject to additional funding. WSD4000 was evaluated in 228 pre-, peri or post-menopausal women over a 4-week period. The results demonstrated that WSD4000 markedly improved sexual function from using the product. 78% of women reported a general improvement in all or most aspects of sex. 78% reported a more satisfying experience and 75% noticed having some increase in interest in having sex; 81% noticed an improvement to their overall sexual function. Overall, 68% of women rated the product 4 or 5 stars. 77% of participants had improved sexual experience after one use which increased to 84% after four uses. More specifically, after four uses: 83% of women experienced improved lubrication (wetness), 82% experienced improved genital sensation, 75% experienced improved arousal, 71% experienced faster arousal, 66% experienced greater ability to achieve orgasm, 61% experienced greater intensity of orgasm, 58% experienced less pain and discomfort during sex. The study also showed that, in general, the product was well tolerated, with only 18% of women experiencing a transient unpleasant sensory effect but many of those still wished to continue to use the product. The sensory effect described as unpleasant in some subjects can be mitigated when commercialised by clear consumer explanation highlighting that this is part of the mode of action of the product. The vast majority (84%) of women in the study claimed to like the sensory feel and lack of aroma of the product. A placebo ('sham' in US regulatory terminology) controlled study was conducted in order to design the most cost-effective clinical study to deliver a statistically significant and clinically meaningful result. WSD4000 was evaluated versus a placebo control in an "in-clinic" cross-over study in 33 pre- and post-menopausal women. WSD4000 was statistically superior to placebo in each of the key measures (arousal, genital sensation and lubrication) at 1 min, 2 min, 3 min, 5 min, 10 min and 15 min intervals. The results give the Company a high degree of confidence that WSD4000 will have superior efficacy to placebo (sham) in the pivotal clinical study and that subject numbers in the study will be at a cost-effective level. Independent research data conducted in the US with 1,000 subjects shows that 60% of women have suffered from at least one symptom of impaired sexual response and function in the prior twelve months. Only 1 in 4 of those impacted women seek professional help. Few women (13%) experience an improvement in symptoms over time and for 37% symptoms get worse over time. Currently, there is no known regulatory approved topical treatment globally for impaired sexual response and function in women that is available over the counter. Market research conducted by Ipsos showed 60% of women have experienced symptoms of sexual dysfunction over the last twelve months and 49% of women want to treat their symptoms. Current US female population between the ages of 22 and 75 is 113 million, of which 68 million experience symptoms. WSD4000 is a project name for our development female sexual health portfolio, starting with the creation of a range of topical gels under our unique platform technology, specifically designed to treat symptoms of sexual dysfunction in women. There is currently no known regulatory approved OTC treatment available for impaired sexual response and function in women. WSD4000 has the potential to be an effective, breakthrough treatment for the common symptoms associated with impaired sexual response and function, such as lack of desire, arousal, lubrication and ability to orgasm. Reported Earnings • Jun 05
Full year 2025 earnings released: UK£0.028 loss per share (vs UK£0.004 profit in FY 2024) Full year 2025 results: UK£0.028 loss per share (down from UK£0.004 profit in FY 2024). Revenue: UK£1.70m (down 88% from FY 2024). Net loss: UK£9.07m (down UK£10.4m from profit in FY 2024). 
